key: cord-0960770-luq14acm
authors: Ramanathan, Kollengode; Shekar, Kiran; Ling, Ryan Ruiyang; Barbaro, Ryan P.; Wong, Suei Nee; Tan, Chuen Seng; Rochwerg, Bram; Fernando, Shannon M.; Takeda, Shinhiro; MacLaren, Graeme; Fan, Eddy; Brodie, Daniel
title: Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis
date: 2021-06-14
journal: Crit Care
DOI: 10.1186/s13054-021-03634-1
sha: 2d1c2ff71b467563cad2127f3b55496810ad0e1e
doc_id: 960770
cord_uid: luq14acm

BACKGROUND: There are several reports of extracorporeal membrane oxygenation (ECMO) use in patients with coronavirus disease 2019 (COVID-19) who develop severe acute respiratory distress syndrome (ARDS). We conducted a systematic review and meta-analysis to guide clinical decision-making and future research. METHODS: We searched MEDLINE, Embase, Cochrane and Scopus databases from 1 December 2019 to 10 January 2021 for observational studies or randomised clinical trials examining ECMO in adults with COVID-19 ARDS. We performed random-effects meta-analyses and meta-regression, assessed risk of bias using the Joanna Briggs Institute checklist and rated the certainty of evidence using the GRADE approach. Survival outcomes were presented as pooled proportions while continuous outcomes were presented as pooled means, both with corresponding 95% confidence intervals [CIs]. The primary outcome was in-hospital mortality. Secondary outcomes were duration of ECMO therapy and mechanical ventilation, weaning rate from ECMO and complications during ECMO. RESULTS: We included twenty-two observational studies with 1896 patients in the meta-analysis. Venovenous ECMO was the predominant mode used (98.6%). The pooled in-hospital mortality in COVID-19 patients (22 studies, 1896 patients) supported with ECMO was 37.1% (95% CI 32.3–42.0%, high certainty). Pooled mortality in the venovenous ECMO group was 35.7% (95% CI 30.7–40.7%, high certainty). Meta-regression found that age and ECMO duration were associated with increased mortality. Duration of ECMO support (18 studies, 1844 patients) was 15.1 days (95% CI 13.4–18.7). Weaning from ECMO (17 studies, 1412 patients) was accomplished in 67.6% (95% CI 50.5–82.7%) of patients. There were a total of 1583 ECMO complications reported (18 studies, 1721 patients) and renal complications were the most common. CONCLUSION: The majority of patients received venovenous ECMO support for COVID-19-related ARDS. In-hospital mortality in patients receiving ECMO support for COVID-19 was 37.1% during the first year of the pandemic, similar to those with non-COVID-19-related ARDS. Increasing age was a risk factor for death. Venovenous ECMO appears to be an effective intervention in selected patients with COVID-19-related ARDS. PROSPERO CRD42020192627. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-021-03634-1.

The use of extracorporeal membrane oxygenation (ECMO) for acute respiratory distress syndrome (ARDS) during outbreaks of emerging infections was previously reported during the 2009 influenza A(H1N1) pandemic, as well as the Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks [1] [2] [3] [4] . More recently, there are reports on the use of ECMO in patients with coronavirus disease 2019 (COVID- 19) , who develop severe ARDS [5, 6] . The Extracorporeal Life Support Organisation (ELSO), the World Health Organization and the Surviving Sepsis Campaign (SSC) Guidelines recommend considering ECMO, in specialised centres, for patients with COVID-19 who develop severe ARDS. In addition, venovenous (VV) ECMO is recommended in selected patients who develop hypoxaemia that is refractory to optimal ventilator management and prone positioning, depending on the availability of resources [7] [8] [9] [10] [11] .

Initial case reports and case series on the use of ECMO for COVID-19-related ARDS were disappointing and raised concerns regarding ECMO use in this patient population [12, 13] . However, several reports of ECMO use have subsequently emerged and have reported considerably better outcomes [5, 6, 14, 15] . The first update of SSC guidelines published recently, suggested that ECMO should be considered only for carefully selected patients with COVID-19 and severe ARDS, with a weak strength of recommendation [16] . Given the resource implications of providing ECMO in a pandemic and variability in the reported outcomes, we performed a systematic review of the literature to summarise outcome data during the first year of the pandemic and identify risk factors for an unfavourable outcomes in order to guide clinical decisionmaking and further research.

This study was registered with PROSPERO (CRD42020192627) and was conducted in adherence with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) Statement [17] . We searched MEDLINE, Embase, Cochrane and Scopus databases from 1 December 2019, to 10 January 2021, using the following keywords and their variations: "extracorporeal membrane oxygenation", "extracorporeal life support", "adult", "SARS-CoV-2" and "COVID-19" (Additional file 1: Table S1 ). We assessed all relevant studies and their citation lists to identify articles for inclusion.

We included data from all studies as well as available online national registries reporting on 10 or more adult patients with COVID-19 supported on ECMO. We excluded any animal or paediatric studies (< 18 years). In the case of overlapping patient data, we included the largest study and excluded any other overlapping studies. Studies from centres that contributed to the ELSO registry report [5] were also excluded to avoid duplication. Two reviewers (RRL and KR) independently screened the articles for eligibility by going through the titles and abstract. Full text of the shortlisted articles was searched thereafter; any conflicts were resolved by consensus or by a third reviewer (KS).

Data were collected independently by two reviewers (RRL and KR) using a prespecified data extraction form; any conflicts were resolved by consensus or by a third reviewer (KS 

Using the Joanna Briggs Institute (JBI) checklists for case series and cohort studies (Additional file 1: Table S2 ), we assessed studies for quality. We assessed the possibility of publication bias using Egger's test. We assessed statistical heterogeneity using the I 2 statistics, the Chi-squared test and visual inspection of the forest plots. We used the PROSPERO CRD42020192627.

Keywords: Extracorporeal membrane oxygenation, Acute respiratory distress syndrome, COVID-19, SARS-CoV-2

Grading of Recommendations, Assessments, Developments and Evaluations (GRADE) approach to assess the certainty of evidence [18, 19] (GRADEpro app available online: https:// www. grade pro. org [accessed on 10 January 2021].

The primary outcome was in-hospital mortality. Secondary outcomes were analysed in the overall cohort and included those remaining in hospital and on ECMO, ICU and hospital length of stay, duration of mechanical ventilation before ECMO, duration of ECMO and complications during ECMO.

We performed statistical analyses in R 3.6.1, using the meta (v4.12-0) and dmetar (v0.0.9000) packages [20] [21] [22] . For continuous variables, we pooled the means from the aggregate data presented in each study as per Wan et al. [23] . We anticipated significant interstudy heterogeneity given the varied presentation of COVID-19 and general lack of guidelines for patient management with ECMO during the early pandemic. As such, we conducted inverse-variance weighted random-effects meta-analyses (DerSimonian and Laird), and 95% confidence intervals (CIs) were computed using the Clopper-Pearson method [24] [25] [26] . Survival outcomes are presented as pooled proportions, while continuous outcomes are presented as pooled means, both with corresponding 95% CIs.

We conducted planned subgroup analyses with continuity correction to include studies with zero events and include geographical region (Asia, Europe, North America and International). Summary-level meta-regression was conducted when at least 6 data points were collected to explore potential sources of heterogeneity or prognostically relevant prespecified study-level covariates [26] . Two sensitivity analyses were conducted for our metaanalysis: analysing the mortality among studies where all patients were supported with VV ECMO and another by excluding studies with a JBI score of less than 7.

Of 2259 references screened, we identified 37 potentially relevant studies and one national database that reported on the outcomes of ECMO in COVID-19 patients ( Fig. 1 ) [5, 6, [12] [13] [14] [15] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] . After excluding 11 studies with overlapping information, we included twenty-two retrospective observational studies with 1896 patients in the meta-analysis. There were 20 single-centre studies and two registry reports (Tables 1 and 2 ). There were 4 studies (422 patients) from Asia, 13 studies (320 patients) from Europe, 4 studies (102 patients) from North America and one multinational study (1035 patients). Modality of ECMO support was reported in 19 studies (1845 patients), and VV ECMO was the predominant technique used (98.6%). In total, 89 patients required venoarterial or venoarterial venous configurations. The pooled patient demographics are summarised in Additional file 1: Table S3 .

Appraisal using the JBI checklist for cohort studies and case series suggested a high level of quality across the included studies for this review. All studies, except two [13, 32] , had scores above 8/10 (Additional file 1: Table S2 ). A summary of the GRADE assessment for certainty of evidence is provided in Additional file 1: Table S4 .

Fifteen studies (1344 patients) reported on PaO 2 /FiO 2 prior to ECMO initiation. The pooled mean PaO 2 /FiO 2 was 67.76 (95% CI 64.72-70.80). Pre-ECMO SOFA score was reported in 11 studies (275 patients) with a pooled mean SOFA score prior to ECMO initiation of 9.62 (95% CI 8.40-10.84). The pre-ECMO ventilatory parameters are summarised in Additional file 1: Table S5 .

Patients with COVID-19 who received ECMO also received various adjunctive therapies prior to ECMO. Pooled incidence of prone positioning prior to ECMO was 85.3% (95% CI 74.6-93.7%) while 96.3% (95% CI 87.6-100.0%) of the patients received neuromuscular blockers. Additional details on the use of inotropic agents, corticosteroids, immuno-modulators and antiviral drugs are highlighted in Additional file 1: Table S6 .

The pooled in-hospital mortality of COVID-19 patients receiving ECMO (22 studies, 1896 patients) was 37.1% (95% CI 32.3-42.0%, high certainty) (Fig. 2) . Two studies had a JBI score lower than 8; pooled in-hospital mortality after excluding these studies was 37.9% (95% CI 32.9-42.9%). There was no evidence of publication bias (Fig. 3 ) (p egger = 0.21). We also analysed the proportion of non-survivors supported on VV ECMO for COVID-19 (17 studies, 1737 patients); pooled in-hospital mortality was 35.7% (95% CI 30.7-40.7%, high certainty) (Additional file 2: Figure S1 ). Mortality, after removal of studies that did not report on pre-ECMO PaO 2 / FiO 2 ratio, was 36.4% (95% CI 30.2-42.9%). Two studies compared mortality rates of patients on mechanical ventilation to those on ECMO; patients needing mechanical ventilation had mortality rates of 47.8% and 63.2% as compared to 46.15% and 57.1%, respectively, in those needing ECMO in these two studies.

There were no overall differences in regional outcomes for COVID-19 patients treated with ECMO (Additional file 3: Figure S2 ).

Univariable meta-regression analysis identified increasing age and reduced ECMO duration as variables associated with mortality, while increasing BMI was protective (Additional file 4: Figure S3 , Additional file 5: Figure S4 and Additional file 6: Figure S5 ). Increasing SOFA score was not associated with higher mortality. Other pre-ECMO factors (PaO 2 /FiO 2 ratio, duration of mechanical ventilation prior to ECMO) or coexisting comorbidities (diabetes mellitus, hypertension, smoking) were not associated with increased mortality (Table 3) . patients more commonly suffered renal, mechanical and infectious complications, and the complication rates in COVID-19 patients were similar to those seen in the EOLIA trial [44] . The review also identified increasing age as a risk factor for increased mortality. The use and efficacy of ECMO in pandemics have been previously reported [1] [2] [3] . The incidence of ECMO use in patients with 2009 influenza A(H1N1)-associated ARDS in Australia and New Zealand was estimated to be 2-6 cases per million [1, 8] , whereas 6% of critically ill patients were supported with ECMO for MERS-CoVassociated ARDS [4] . A meta-analysis of the studies that reported on the use of ECMO for the 2009 influenza A(H1N1) pandemic showed an overall mortality of 35% in a relatively younger population (mean age 40 years) [2] . Patients with MERS-CoV who were supported with ECMO had a higher reported mortality of 40-70% [3] . By comparison, this review demonstrated that the cumulative mortality for patients with COVID-19 receiving ECMO support was 37.1% in a group of patients who were older (mean age 51.6 years) and were predominantly men. These results may also alleviate some concerns regarding VV ECMO use in the context of COVID-19-related ARDS [13, 47] . During a pandemic, ECMO use will be subject to resource availability, given that prolonged ECMO support may be needed in these patients and the ELSO guidelines provide recommendations to assist clinicians in selecting patients judiciously in order to maximise benefit to patients with available resources [7, 8] . Our meta-regression analysis showed that outcomes appear worse in patients with increasing age. Clinicians may have to exercise considerable discretion when offering ECMO to older patients during a pandemic where resources may be stretched, with no definitive age cut-off to guide this decision-making. Interestingly, greater duration of ECMO support and illness severity (SOFA score) were not independently associated with death. The duration of VV ECMO support was longer when compared with patients in the EOLIA trial receiving ECMO (median: 15.92 days vs 11 days). Prolonged ECMO runs outside COVID-19 have been reported with good success [48] . However, the association between prolonged ECMO duration and improved mortality seen in this study stems likely from immortal time bias [49] (49) , commonly reported in observational studies. For patients on ECMO, such individuals must survive long enough to be weaned off, whereas their peers have no minimum survival requirements. The mean duration of mechanical ventilation prior to ECMO was 4.4 days and was not associated with mortality in the meta-regression analysis. Higher SOFA score was not an independent predictor for death in this review, a finding that contradicts previously published experience [50] . SOFA scores in patients requiring ECMO for COVID-19 can be variable, depending on their underlying phenotype [51] . Therefore, caution should be exercised when placing patients with advanced extrapulmonary organ failures on ECMO. Even though VV ECMO appears to be a viable therapy, the potential need for prolonged ECMO Alnababteh 2020

Barbaro 2020

Charlton 2020 Cousin 2020

Falcoz 2020

Guihaire 2020

Huette 2020

Jackel 2020

Jang 2020

Jozwiak 2020

Le Breton 2020 Masur 2020

Mustafa 2020

Roedl 2020

Schmidt 2020

Shih 2020

Takeda 2020

Yang 2020

Zayat 2020

Zeng 2020

Zhang 2020 p < 0.05 p < 0.025 p < 0.01 support may be a significant consideration when selecting patients during the pandemic. Other uncertainties regarding the long-term outcomes and the maximum duration of ECMO where recovery is still possible remain and may become clearer as more data becomes available [52] . Strengths of this study include robust inclusion criteria and relevant exclusion criteria. Our review included 22 studies covering 6 geographical regions. We reduced confounding by elucidating factors correlating with mortality via subgroup analysis and meta-regression. Singlecentre data that overlapped with international registries were excluded thereby avoiding duplication of data. We assessed study quality using a validated tool and assessed certainty in our estimates using GRADE. Nonetheless, we recognise several limitations of this study. Firstly, we included studies written only in English for the review. The variability in ECMO initiation and management across centres and regions as well as additional variability during the pandemic may have contributed to increased heterogeneity in our results. The outcomes of patients who were still in hospital or on ECMO at the time of publication were not known. Given that most of these studies were single-centre retrospective studies, these aspects could have introduced various confounders given the lack of risk adjustment or propensity score weighting. Even though the paper from ELSO registry contributed to a majority of patients in the review, the overall weightage to the entire analysis was only 12%, highlighting that the data were not skewed by one study. In addition, manuscripts published from centres that contributed to the ELSO registry report were excluded to avoid duplication. Meta-regression analyses are also inherently constrained by a lack of power, resulting in an increased risk of type 2 errors. This is further compounded by the fact that certain important variables, such as pre-ECMO SOFA scores, were only available in 11 studies, which might reduce the strength of the association between these variables and mortality Nonetheless, there was no publication bias in the studies included and JBI critical appraisal deemed most of the articles as high quality and suitable for inclusion while the GRADE assessment suggested a high certainty of evidence for the primary outcome.

The outcomes from VV ECMO use in patients with COVID-19-related severe ARDS during the early pandemic appear similar to those reported in patients who receive VV ECMO for non-COVID-19-related severe ARDS. Increasing age is a risk factor for death. The duration of ECMO appears to be prolonged in patients with COVID-19 and a prolonged ECMO run was not in itself a predictor of death.

Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome

Extracorporeal membrane oxygenation in severe influenza infection with respiratory failure: a systematic review and meta-analysis

Extracorporeal membrane oxygenation for severe Middle East respiratory syndrome coronavirus

ECMO use in COVID-19: lessons from past respiratory virus outbreaks-a narrative review

Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study

Extracorporeal Life Support Organization Coronavirus Disease 2019 Interim Guidelines: a consensus document from an international group of interdisciplinary extracorporeal membrane oxygenation providers

Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases

Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected: Interim guidance

Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)

Mortality and costs following extracorporeal membrane oxygenation in critically ill adults: a population-based cohort study

Extracorporeal membrane oxygenation for coronavirus disease 2019-induced acute respiratory distress syndrome: a multicenter descriptive study

Prognosis when using extracorporeal membrane oxygenation (ECMO) for critically ill COVID-19 patients in China: a retrospective case series

Nationwide system to centralize decisions around extracorporeal membranous oxygenation use for severe COVID-19 pneumonia in Japan

Extracorporeal membrane oxygenation for patients with COVID-19 in severe respiratory failure

Surviving Sepsis Campaign Guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

GRADE guidelines: 7. Rating the quality of evidence-inconsistency

Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients

Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol

VA-ECMO for post-cardiotomy cardiogenic shock: The Oklahoma ECMO Network Experience

Clinical correlation with changing radiographic appearance during partial liquid ventilation

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

Meta-analysis in clinical trials

The use of confidence or fiducial limits illustrated in the case of the binomial

Vascular complications of extracorporeal membrane oxygenation: a systematic review and meta-regression analysis

Extracorporeal membrane oxygenation for COVID-19 induced hypoxia: single-center study

SARS-CoV-2 and ECMO: early results and experience

Comparing SARS-CoV-2 and influenza A(H1N1)pdm09-infected patients • fast, convenient online submission • thorough peer review by experienced researchers in your field • rapid publication on acceptance • support for research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year submit your research ? Choose BMC and benefit from: ? Choose BMC and benefit from: requiring ECMO-a single-centre, retrospective observational cohort experience

SARS-CoV-2 versus influenza associated acute respiratory distress syndrome requiring veno-venous extracorporeal membrane oxygenation support

Extracorporeal membrane oxygenation for critically ill patients with COVID-19-related acute respiratory distress syndrome: worth the effort?

Specific considerations for venovenous extracorporeal membrane oxygenation during coronavirus disease 2019 pandemic

Extracorporeal membrane oxygenation for respiratory failure in COVID-19 patients: outcome and time-course of clinical and biological parameters

Outcome of acute respiratory distress syndrome requiring extracorporeal membrane oxygenation in Covid-19 or influenza: a single-center registry study

Clinical course of COVID-19 patients treated with ECMO: a multicenter study in Daegu

Extracorporeal membrane oxygenation for refractory COVID-19 acute respiratory distress syndrome

Use of venovenous extracorporeal membrane oxygenation in critically-ill patients with COVID-19

A double-edged sword: neurologic complications and mortality in extracorporeal membrane oxygenation therapy for COVID-19-related severe acute respiratory distress syndrome at a tertiary care center

Mechanical ventilation and mortality among 223 critically ill patients with coronavirus disease 2019: a multicentric study in Germany

Venovenous extracorporeal membrane oxygenation for patients with refractory coronavirus disease 2019 (COVID-19): multicenter experience of referral hospitals in a large health care system

Role of extracorporeal membrane oxygenation in critically ill COVID-19 patients and predictors of mortality

Veno-venous extracorporeal membrane oxygenation in coronavirus disease 2019: a case series

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome

Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial

ECMO for severe ARDS: systematic review and individual patient data meta-analysis

Extracorporeal membrane oxygenation for coronavirus disease 2019-induced acute respiratory distress syndrome: a multicenter descriptive study

Outcome of adult respiratory failure patients receiving prolonged (>/=14 Days) ECMO

Immortal time bias in critical care research: application of time-varying Cox regression for observational cohort studies

Venovenous extracorporeal membrane oxygenation in adult respiratory failure: Scores for mortality prediction

Phenotypes of severe COVID-19 ARDS receiving extracorporeal membrane oxygenation

What's new in ECMO for COVID-19?

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

The authors would like to acknowledge Satoru Hashimoto for his help with the analysis of the ECMO patients on the live dashboard at the Japan ECMOnet for COVID-19 website. Dr Shekar acknowledges research support from Metro North Hospital and Health Service.

The online version contains supplementary material available at https:// doi. org/ 10. 1186/ s13054-021-03634-1. Table S1 to S6. 

The study was designed by KS and KR. RRL and KR screened the articles, assessed the risk of bias and extracted the data. RPB and ST aided with the data from Extracorporeal Life Support Organisation and Japan ECMOnet for COVID-19 registries, respectively. SNW helped with the search criteria. RRL analysed and interpreted the data under the supervision of CST and KR. BR and SF helped with GRADE analysis. Tables and figures were produced by RRL. KR and KS had primary responsibility of writing the manuscript, to which all authors contributed to and revised. DB, EF, RPB and GM critically revised the manuscript for important intellectual content. All authors provided critical conceptual input, interpreted the data analysis, read and approved the final draft.

Not applicable.

All data generated or analysed during this study are included in the published studies and their supplementary information files.

Ethics approval and consent to participate Not applicable.

Not applicable.